A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluationAleix Prat, PierFranco Conte, Alba A. Brandes et al.|The Lancet Oncology|2020Cited by 75
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancerGaia Griguolo, Valentina Guarneri, Maria Vittoria Dieci et al.|npj Breast Cancer|2021Cited by 25
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancerMaria Vittoria Dieci, Valentina Guarneri, PierFranco Conte et al.|JNCI Journal of the National Cancer Institute|2023Cited by 14
Abstract PS5-14: Gene-expression profiling and response to neoadjuvant endocrine treatment in the phase II LETLOB trialGaia Griguolo, Valentina Guarneri, Maria Vittoria Dieci et al.|Cancer Research|2021Cited by 3
Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trialGaia Griguolo, Valentina Guarneri, Maria Vittoria Dieci et al.|Annals of Oncology|2019Cited by 2